Elicio Therapeutics, Inc. (ELTX)
ELTX Stock Price Chart
Explore Elicio Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ELTX price movements and trends.
ELTX Company Profile
Discover essential business fundamentals and corporate details for Elicio Therapeutics, Inc. (ELTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Feb 2021
Employees
32.00
Website
https://elicio.comCEO
Robert T. Connelly
Description
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
ELTX Financial Timeline
Browse a chronological timeline of Elicio Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.53.
Earnings released on 11 May 2026
EPS came in at -$0.65 falling short of the estimated -$0.49 by -32.65%.
Earnings released on 12 Mar 2026
EPS came in at -$0.49 falling short of the estimated -$0.47 by -4.26%.
Earnings released on 13 Nov 2025
EPS came in at -$0.60 surpassing the estimated -$0.62 by +3.23%.
Earnings released on 7 Aug 2025
EPS came in at -$0.66 surpassing the estimated -$0.69 by +4.35%.
Earnings released on 13 May 2025
EPS came in at -$0.87 falling short of the estimated -$0.67 by -29.85%.
Earnings released on 31 Mar 2025
EPS came in at -$1.02 falling short of the estimated -$0.94 by -8.51%, while revenue for the quarter reached $1.17m .
Earnings released on 13 Nov 2024
EPS came in at -$1.39 falling short of the estimated -$0.81 by -71.60%.
Earnings released on 13 Aug 2024
EPS came in at -$0.64 surpassing the estimated -$0.96 by +33.33%.
Earnings released on 15 May 2024
EPS came in at -$1.15 falling short of the estimated -$1.09 by -5.50%.
Earnings released on 13 Feb 2024
EPS came in at -$1.75 falling short of the estimated -$0.78 by -124.36%.
Earnings released on 9 Nov 2023
EPS came in at -$1.27 falling short of the estimated -$0.80 by -58.75%.
Earnings released on 11 Aug 2023
EPS came in at -$2.61 surpassing the estimated -$5.70 by +54.21%.
Stock split effective on 2 Jun 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2023
EPS came in at -$0.15 surpassing the estimated -$0.54 by +72.22%.
Earnings released on 31 Dec 2022
EPS came in at -$2.15 .
Earnings released on 30 Sept 2022
EPS came in at -$2.27 surpassing the estimated -$3.20 by +29.16%.
Earnings released on 30 Jun 2022
EPS came in at -$2.37 surpassing the estimated -$4.63 by +48.94%, while revenue for the quarter reached $653.00k , missing expectations by -51.63%.
Earnings released on 31 Mar 2022
EPS came in at -$4.75 , while revenue for the quarter reached $1.65m .
Earnings released on 31 Dec 2021
EPS came in at $4.97 , while revenue for the quarter reached $25.94m .
Earnings released on 29 Sept 2021
EPS came in at -$5.26 , while revenue for the quarter reached $1.46m .
ELTX Stock Performance
Access detailed ELTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
